INCR INC Research Holdings Inc

Syneos Health Leaders Recognized as PM360 2023 ELITE Award Recipients

Syneos Health Leaders Recognized as PM360 2023 ELITE Award Recipients

Company Executives Honored for Notable Biopharmaceutical Industry Impact

MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual ELITE Awards.

The PM360 ELITE Awards recognize individuals in 19 categories in the life sciences industry who exemplify the following traits: Exceptional Leaders, Innovators, Transformers, and Entrepreneurs (ELITE).

  • Maria Fotiu is honored in the Strategists category for constantly leading her team toward operational excellence. Driven by a mission to reimagine clinical trials, she has created an operating model at Syneos Health that delivers the agile and hybrid clinical trials of the future.
  • Sayee Natarajan is recognized in the Transformational Leaders category for the role he has played in reshaping the way the industry leverages data to understand the patient journey, including better understanding how to reach diverse patient populations and quantifying the doctors likely to reach those patients.
  • Greg Christie is featured in the Tech-know Geeks category for the work StudyKIK has deployed using technology to redefine and improve the clinical trial process. Among his team’s latest innovations are mobile applications for patients, a management portal that simplifies operations for research sites and an informative analytics dashboard for sponsors.

“It is an honor to have three of our extraordinary leaders recognized with this industry distinction,” said Michelle Keefe, CEO, Syneos Health. “The work Maria, Sayee and Greg do on a daily basis directly impacts patients’ lives, helping important therapies make it to market faster and in more meaningful ways. They are industry pioneers and we are fortunate to have them as part of the Syneos Health team – their passion, expertise and customer commitment enable us to achieve our Vision to shorten the distance from lab to life.”

This year, more than 500 submissions were received, and nominees were evaluated and selected by the PM360 editorial staff based on their accomplishments, testimonials from their bosses, clients, and colleagues, and supporting evidence that reflects the impact of their efforts.

“The life sciences and healthcare at large are constantly evolving industries that are always in search of better ways to care for and communicate with patients, and that change isn’t possible without people like this year’s ELITE 100,” says Anna Stashower, CEO and Publisher of PM360. “These individuals and teams are reshaping how things are done to make necessary improvements such as more convenient clinical trials for patients, shorter time to diagnosis for rare disease patients, the elimination of systemic barriers in media targeting, better care for glaucoma patients, greater attention paid to caregivers, expanding communication channels into dating apps, and much more. The impact of their work cannot be understated and we are honored to recognize their contributions to our industry.”

All of the 100 winners were profiled in PM360's May 2023 issue. You can read their profiles online .

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

To learn more about how we are Shortening the distance from lab to life®, visit or .

Investor Relations Contact:Press/Media Contact:
Press/Media Contact:

Senior Vice President, Investor Relations





Gary Gatyas

Executive Director, External Communications







EN
16/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INC Research Holdings Inc

 PRESS RELEASE

Syneos Health Closes Transaction with Private Investment Firms

Syneos Health Closes Transaction with Private Investment Firms Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers MORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As a result of the...

 PRESS RELEASE

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Syneos Health Names Terttu Haring President, Clinical Sites & Patients Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organizat...

 PRESS RELEASE

Syneos Health and Oracle to Expand Relationship to Accelerate Patient ...

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient pop...

 PRESS RELEASE

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Bill...

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Hea...

 PRESS RELEASE

Syneos Health Stockholders Approve Agreement with Private Investment C...

Syneos Health Stockholders Approve Agreement with Private Investment Consortium MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier toda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch